CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,393,015 | +18499.5% | 1,568,948 | +13559.7% | 0.00% | – |
Q2 2023 | $125,772 | -35.9% | 11,486 | -49.0% | 0.00% | – |
Q1 2023 | $196,270 | +178.5% | 22,508 | +100.2% | 0.00% | – |
Q4 2022 | $70,475 | +80.7% | 11,240 | +0.2% | 0.00% | – |
Q3 2022 | $39,000 | +18.2% | 11,215 | 0.0% | 0.00% | – |
Q2 2022 | $33,000 | -5.7% | 11,215 | -0.5% | 0.00% | – |
Q1 2022 | $35,000 | +3400.0% | 11,275 | +4617.6% | 0.00% | – |
Q1 2021 | $1,000 | – | 239 | +23800.0% | 0.00% | – |
Q1 2020 | $0 | – | 1 | -97.4% | 0.00% | – |
Q4 2019 | $0 | -100.0% | 39 | -88.5% | 0.00% | – |
Q3 2019 | $2,000 | – | 339 | +769.2% | 0.00% | – |
Q2 2019 | $0 | -100.0% | 39 | -100.0% | 0.00% | – |
Q1 2019 | $1,630,000 | -62.2% | 122,739 | -77.6% | 0.00% | -100.0% |
Q4 2018 | $4,310,000 | -77.0% | 547,528 | -67.6% | 0.00% | -50.0% |
Q3 2018 | $18,741,000 | -42.2% | 1,691,425 | -30.0% | 0.00% | -50.0% |
Q2 2018 | $32,421,000 | -55.3% | 2,415,837 | -56.7% | 0.00% | -55.6% |
Q1 2018 | $72,538,000 | +238.8% | 5,584,117 | +139.9% | 0.01% | +200.0% |
Q4 2017 | $21,413,000 | +14.1% | 2,327,520 | 0.0% | 0.00% | +50.0% |
Q3 2017 | $18,759,000 | – | 2,327,520 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |